Netscientific Share Discussion Threads

[blakieboy7] 11/3/2021 16:03

PDSB now 60% up

[albert arthur] 11/3/2021 15:52

If PDSB was to get to the cap of Moderna Inc before it’s vaccine announcement 8b, then our 5.75% investment would be worth 460m. On this cap today and with the 5% float. This is an ISA job and a solid investment. PDSB will become a unicorn that is for sure. I’m not trading this, in the long pot with my other gems.

[blakieboy7] 11/3/2021 15:43

Pdsb up 48%

[blakieboy7] 11/3/2021 15:41

I think this rise could have legs finally

[nextlink] 11/3/2021 15:38

Hasn't anything positive to say about any share.
Richardp1911 Mar '21 - 15:36 - 2834 of 2834 (Filtered)

[richardp19] 11/3/2021 15:34

Dropping like a stone

[blakieboy7] 11/3/2021 15:30

70p, nice!!!

[the stigologist] 11/3/2021 14:28

PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to Approximately US$60m


FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech’s proprietary Versamune® T-cell activating technology, today announced that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil.

MCTI intends to start making the funds available to prepare to perform a combined Phase 1/2 clinical trial, upon authorization by the Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (Anvisa) to initiate the proposed Versamune®-based COVID-19 vaccine clinical program in Brazil.

The pre-IMPD package for the Phase 1/2 trial is currently under review by Anvisa and the trial is anticipated to begin by Q2/3 2021. The majority of the capital provided by MCTI will fund the manufacturing process scale up, production and the Phase 3 trial, pending the results of the Phase 1/2 trial. The consortium members will work under a mutually agreed work plan to guide the vaccine efficiently through development in compliance with regulatory standards. The consortium anticipates working to initiate manufacturing scale up activities in the second quarter.

This award is based on the preclinical studies of the Versamune®-based COVID-19 vaccine. The vaccine combines PDS Biotech’s Versamune® T-cell activating platform technology with a SARS-CoV-2 recombinant protein derived from the spike (S) protein. Notably, the protein in this fully synthetic vaccine includes conserved and non-mutating regions of the virus. The vaccine has demonstrated strong potential in preclinical studies to efficiently promote the induction of killer (CD8+) and helper (CD4+) T-cells that recognize and induce immune responses against such non-mutating regions of the virus. The protein also includes regions of the spike protein that result in the induction of neutralizing antibodies.

The Phase 1 and 2 trials, which will be run together, are anticipated to enroll approximately 360 patients and will assess the safety and efficacy of the vaccine as well as both the antibody and killer T-cell responses induced by the vaccine to the novel coronavirus. The clinical trials are planned to be conducted in Brazil.

“PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune®-based COVID-19 vaccine into the clinic,” said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.“ The preclinical results demonstrate the vaccine’s potential to induce a broad range of robust anti SARS-CoV-2 immune responses. The rapidly increasing number of SARS-CoV-2 mutations highlights the need for novel, second generation vaccines capable of generating both killer and helper T-cells that can recognize and attack conserved and non-mutating regions of the virus. We applaud Farmacore Biotechnology and Blanver Farmoquímica for reaching this important milestone and look forward to the results of the planned human clinical trials and hopefully a rapid advancement towards commercialization of the product. These clinical trials will also advance our understanding of the potential for novel Versamune®-based vaccines to provide long-term protection against infection with viruses with pandemic potential such as SARS-CoV-2.”

“We are excited to continue advancing the program with PDS Biotech, and we are thrilled to have had the continued support of the Brazilian government as we finalize clinical study protocols with Anvisa for human testing of the novel vaccine combining the Versamune® T-cell activating technology with the SARS-CoV-2 recombinant protein antigen. We are proud to advance this promising medicine in Brazil in the fight against this global pandemic,” said Helena Faccioli, CEO of Farmacore Biotechnology.

As the license holder of PDS0203 in Latin America, Farmacore Biotechnology will continue to lead the regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization, to conduct clinical trials in Brazil. PDS Biotech will continue to contribute scientific expertise and operational support and oversee scale up of the manufacturing process. Blanver Farmoquímica will manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America.

All funding is contingent on the availability of financial resources within the MCTI, and The Secretary for Research and Scientific Training of the MCTI has committed to making every effort to finance all clinical and development stages of the program.

[the stigologist] 11/3/2021 14:23

@Pharmdca a big biotech PI investor with huge twitter following is buying more PDSB in the 4s

This has potential to 'do an OCGN' which 50x in a few weeks on them getting into vaccine game

[albert arthur] 11/3/2021 14:18

It's 30% up stateside Pre-market trading is not for all. Let's see what happens. 60m investment is nearly as big as their cap. I'll leave you to google what a cap is.

[albert arthur] 11/3/2021 14:10

02:30pm novice.

[the stigologist] 11/3/2021 14:05

Yanks not woken up yet...

[the stigologist] 11/3/2021 14:04

Wowzers

Remember the Brazil funding would just be potential pathfinder to the US following suit and also funding PDS Covid Vaccine !

And the Covid vaccine stuff is just a 'sideshow' to the Cancer Vaccine potential of PDSB

And PDSB is just a sideshow to NSCI Glycotest stake !

[albert arthur] 11/3/2021 13:59

Expect movement when the yanks wake up. RNS landed there 1:30pm it's 24% up pre-market. 80m cap there.

[blakieboy7] 11/3/2021 13:57

Finally woken up!!

[samsung2020] 11/3/2021 13:55

Great news.

[albert arthur] 11/3/2021 13:54

$PDSB PDS Biotech COVID-19 Vaccine Consortium Receives a US$60 Million Commitment from Brazil's MCTI to Fund Clinical Development and Commercialization of PDS0203 #CovidVaccine pdsbiotech.com/investors/news...https://twitter.com/pdsbiotech/status/1370004736011874307?s=21

[albert arthur] 11/3/2021 13:53

Check this out: 60m funding in PDS:https://twitter.com/albert__arthur/status/1370008805967331330?s=21